热门资讯> 正文
OKYO Pharma报告其神经性角膜疼痛治疗的长期益处
2025-03-31 22:01
- OKYO Pharma (NASDAQ:OKYO) said on Monday that urcosimod, its neuropathic corneal pain treatment, has shown to be stable for over two and a half years in single-use ampoules used for administration to patients.
- Neuropathic corneal pain is a condition causing severe pain and sensitivity of the eyes, face, or head.
- "We are also conducting long-term stability testing of urcosimod at room temperature, and so far, the 3-month results at room temperature are at or above 100%," said Raj Patil, Ph.D., Chief Scientific Officer of OKYO Pharma.
More on OKYO Pharma
- OKYO Pharma receives $1.4 million in non-dilutive funding, stock up
- Seeking Alpha’s Quant Rating on OKYO Pharma
- Historical earnings data for OKYO Pharma
- Financial information for OKYO Pharma
推荐文章
美股机会日报 | 特朗普放大招！9万亿养老金即将杀入加密市场；美联储主席候选人支持7月降息
一周财经日历 | 特斯拉、谷歌财报重磅来袭！维立志博将于下周五登陆港交所
一图看懂 | 港股上半年IPO募资额登顶全球！中签就赚一万港币的“大肉签”你参与了吗？
华盛早报丨重大突破！三大加密货币法案众议院闯关成功；美联储，降息大消息
黄仁勋年内三度访华！H20重返中国市场，释放了什么信号？
创新药行情彻底爆发！维立志博-B打新半日孖展超购130倍，冻资近150亿港元
新股申购 | 维立志博-B入场费3535.30港元！引入腾讯、易方达等基石投资者
7月财报预告丨迎关税考验！特斯拉、台积电放榜在即，美股能否守住涨势？
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
